From: A review on the role of cyclin dependent kinases in cancers
Tumor type | Targets/ Regulators and Signaling Pathways | Cell line | Function | References |
---|---|---|---|---|
Adrenocortical carcinoma | CENPF | SW13 | CENPF/CDK1 signaling pathway was found to regulate the G2/M-phase, thus enhancing progression of adrenocortical carcinoma | [6] |
Bladder cancer | PVT1/miR-31/CDK1 axis | RT4, T24, BIU‐87, and 5673 | PVT1 facilitated proliferation, migration, and invasion via down-regulating miR-31 to enhance CDK1 expression | [7] |
TFCP2L1 | Murine R1, E14TG2a, and gcOct4‐GFP ESCs, HBlEpC, J82, T24, 5637, HT1197, HT1376, and RT4 | CDK1-mediated TFCP2L1 phosphorylation was found to have essential role in bladder cancer | [8] | |
Cdc25C, Chk1, CDK1-cyclin B1 complex, Myt1, Wee1, phospho-Cdc25C (Ser216), Gadd45α, and 14-3-3 proteins | SCaBER, 5637, T24, UMUC3, TCCSUP, SV-HUC, T24, T24T, TCCSUP, UMUC1, and SV-HUC | Protein kinase D inhibitor “CRT0066101” suppressed expression of Cdc25C, which activates CDK1, but activated Chk1, that inhibits CDK1 and indirectly reduced the CDK1-cyclin B1 complex activity, so it inhibited bladder cancer growth by blocking cell cycle at G2/M | [9] | |
Breast cancer | KIAA1429 | MCF-7, BT474, SUM1315, MDA-MB-231 and MCF-10A | KIAA1429 was found to positively regulate CDK1 | [10] |
_ | MCF-7 and MDA-MB-231 | ∆ CDK1: ↓ migration and invasion | [11] | |
UBAP2L | MCF-7, ZR-75-30, BT-474, T-47D and MDA-MB-468, and MCF-10A | ∆ UBAP2L: ↓ proliferation, colony formation, CDK1 levels, and ↑ cell cycle arrest | [12] | |
miR-424 | MDA-MB-231, HCC1937, MCF-10A, and HEK-293 T | ↑↑ miR-424: ↓ proliferation and ↑ cell cycle arrest via targeting CDK1 | [17] | |
NUSAP1, and DLGAP5 | MCF-7 | ∆ NUSAP1: ↓ proliferation, migration, and invasion via regulating CDK1 and DLGAP5 expression and ↑ sensitivity to E-ADM | [18] | |
RBM7 | SUM-1315, MCF-7, BT474, ZR-75-1, and MDA-MB-231 | RBM7 was found to bind to the 3'-UTR of CDK1 transcript, which is involved in the stability of CDK1 mRNA RBM7 plays its oncogenic role by increasing the levels of CDK1 | [19] | |
Burkitt lymphoma | miR-129 and iASPP | Raji and CA46 | miR-129 was found to target CDK1, so it is involved in inhibiting iASPP phosphorylation and reducing proliferation ∆ CDK1: ↓ iASPP S84/S113 phosphorylation, so blocked iASPP nucleus localization | [13] |
Cancer stem cells | RAS/MAPK/CDK1 pathway, SOX2 | p53 − / − MEFs, HRASV12-expressing p53 − / − MEF, TIG-3, and TIG-3–SMR, HCT116, SW480, DLD1, HCC827, and H460 | RAS/MAPK/CDK1 pathway induces enhanced O-GlcNAc modification and is required for expression of SOX2 and cancer stem cells generation | [14] |
miR-143-3p and miR-495-3p | HcerEpic, C4-1, HeLa, SiHa, and Caski | CDK1 was a target of miR-143-3p and miR-495-3p ↑↑ miR-143-3p or miR-495-3p: ↓ proliferation, migration, invasion, viability and ↑ apoptosis | [20] | |
NCK1-AS1/miR-6857/CDK1 axis | CerEpiC, HeLa, C33A and SiHa and CaSki | ∆ NCK1-AS1: ↓ proliferation and invasion, and ↑ cell cycle arrest NCK1-AS1 was found to sponge miR-6857, so regulate CDK1/6 protein translation | [21] | |
Cholangiocarcinoma | _ | CCKS-1, TFK-1 and HUCCT-1 | ∆ CDK1: ↓ proliferation and invasion, and ↑ cell cycle arrest | [22] |
PSMC2 | HUCCT1, QBC939, RBE, and HCCC-9810 | ∆ PSMC2: ↓ proliferation, cell migration, ↑ cell cycle arrest, and apoptosis PSMC2 eas found to regulate its role via regulating CDK1 | [23] | |
Colorectal cancer | KCTD12 | HCT116 and HT29 | Adefovir dipivoxil: ↓ proliferation, tumorigenesis, and ↑ G2 phase arrest via disrupting the CDK1-KCTD12 interaction ↑↑ CDK1: ↑ vemurafenib resistance | [16] |
MEK/ERK pathway | HT-29, RKO, VACO432, WiDr, DLD1, SW620, DiFi, A375, A19, T29 and VACO432, VT1, NB7 | ∆ CDK1: ↑ sensitivity to apoptosis A MEK/ERK inhibitor targeting CDK1 has effective role in reduction of cell proliferation | [15] | |
miR-378a-5p | SW480, HCT116, SW620, HT-29 and NCM460 | CDK1 was a target of miR-378a-5p ↑↑ miR-378a-5p: ↓ proliferation and migration ↑↑ CDK1: ↑ proliferation and migration | [24] | |
DPP3 | DLD-1, SW480, HCT 116, and RKO | ∆ CDK1: ↓ inhibitory effects of DPP3 knockdown ∆ DPP3: ↓ proliferation, migration, ↑ apoptosis and cell cycle arrest DPP3 was found to regulate CRC via CDK1 | [25] | |
SNHG4/ miR-590-3p/CDK1 axis | FHC, HCT8, LoVo, HCT116, SW620, and HT29 | ∆ SNHG4: ↓ proliferation, viability, metastasis, and colony formation via targeting miR-590-3p and regulating CDK1 | [26] | |
NFE2L3, DUX4 | HCT116 and HT29 | ∆ NFE2L3: ↑ levels of DUX4, which is an inhibitor of CDK1 | [27] | |
SNRPA1 | SW480, RKO, HT-29, HCT116, and HEK293T | ∆ SNRPA1: ↓ proliferation, ↑ apoptosis SNPRA1 was found to regulate CDK1 in CRC | [28] | |
Endometrial carcinoma | miR-1271 | ECC-1, RL95-2, AN3 CA, and T-HESC | ↑↑ miR-1271: ↓ cell proliferation, ↑ apoptosis via targeting CDK1 | [29] |
Esophageal squamous cell carcinoma | FAM135B, PI3K/Akt/mTOR signaling pathway | KYSE150, ECA109, TE-13, TE-10 and TE-1 | ∆ FAM135B: ↓ colony formation and ↓ cell cycle protein expression (pP53, CDK1), ↑ cell cycle arrest and ↑ radiosensitivity through regulating PI3K/Akt/mTOR | [30] |
Gastric cancer | CASC11 and miR-340-5p | GES-1, MKN7, KATOIII and AZ521 | ∆ CASC11: ↓ proliferation, ↑ apoptosis and cell cycle arrest CASC11 regulated CDK1 via targeting miR-340-5p | [31] |
ESRRA, CDC25C-CDK1-Cyclin B1 pathway | HGC27, BGC823, MGC803, SGC7901 and GES-1 | ∆ ESRRA: ↓ cell viability, proliferation, migration, and invasion, EMT process, and ↑ apoptosis ESRRA/DSN1/CDC25C-CDK1-Cyclin B1 pathway was involved in in GC development | [32] | |
CDCA5 | MGC-803, SGC-7901, and BGC-823 | ∆ CDK1: ↓ proliferation, colon formation, migration, and invasion CDK1 and CDCA5 were co-expressed in GC cells | [33] | |
ISL1 | BGC823, MGC803, MKN28, and GES1 | is CDK1 phosphorylated ISL1 at serine 269, thus promoted proliferation | [34] | |
Glioblastoma | p50, BCL-3, NF-κB | U87, A172, T98, U251, and GBM34 | CDK1 was found to be up-regulated by temozolomide in an NF-κB related manner ∆ CDK1: ↑ sensitivity cells to temozolomide | [35] |
Glioma | FOXD2-AS1/miR-31/CDK1 axis | SVG p12, T98, LN229, U87, U251, and 293FT | ∆ FOXD2-AS1: ↓ proliferation, and ↑ cell cycle arrest FOXD2-AS1 was found to sponge miR-31, so regulated CDK1 levels | [36] |
Hepatocellular carcinoma | PDK1/β-Catenin | MHCC97H (97H), LO2 and 97H liver cancer stem cells | ∆ CDK1/PDK1/β-Catenin: ↓ EMT process RO3306 and sorafenib combination: ↓ 97H CSC growth | [37] |
DEPDC1B | HEP3B2.1-7, SK-HEP-1, huh-7, and HCCLM3 | ∆ DEPDC1B: ↓ proliferation, migration, colony formation, and ↑ G2 phase arrest, and cell apoptosis The function of DEPDC1B was found to be mediated by CDK1 | [38] | |
miR-1271-5p | SMMC-7721 and HuH-7 | ↑↑ miR-1271-5p: ↓ proliferation and ↑ radiosensitivity via targeting CDK1 | [39] | |
CDK1-PLK1/SGOL2/ANLN pathway | SK-Hep1 | ∆ CDK1: ↓ expression of PLK1, ANLN, and SGOL2 and resulted in a disordered cell cycle | [40] | |
Upf1/SNORD52/CDK1 pathway | Huh7, HepG2, Hep3B, SK-Hep1, HCCLM9, HCCLM3, and HL-7702 | ∆ SNORD52: ↓ ↓ migration and invasion, and ↑ cell cycle arrest SNORD52 was found to regulate CDK1 by increasing the stability of CDK1 proteins | [41] | |
Leukemia | PLK1, Aurora B, and TRF1 | HL-60 | ∆ CDK1: ↓ proliferation, ↑ cell cycle arrest via reducing the phosphorylation of PLK1 and Aurora B and negatively regulating TRF1 | [42] |
Lung cancer | Sox2 | A549 and NCI-H520 | ∆ CDK1: ↑ chemotherapeutic sensitivity CDK1/Sox2 axis was found to regulate the stemness | [43] |
CASC11, miR-302 | A547, H157, SPC-A-1 and 16HBE | ∆ CASC11: ↓ proliferation via targeting miR-302 and regulating CDK1 | [44] | |
miR-34c-3p | A549, CALU-1, and HCC827 | ↑↑ miR-34c-3p: ↓ proliferation, ↑ apoptosis and in KRASmut cells via targeting CDK1 | [45] | |
NCK1-AS1 | A549, NCI-H1299, PC-9 and NCI-H1650 | ∆ NCK1-AS1 (which regulated CDK1): ↓ proliferation | [46] | |
miR-186 | A549, H1299, H460, and BEAS-2 | Lycorine treatment: ↑ levels of miR-186 and ↓ levels of CDK1: ↓ proliferation and ↑ apoptosis CDK1 was a target of miR-186 | [47] | |
GP130/STAT3 signaling pathway | A549, 1792, and HEK293T | ↑↑ Iron-dependent CDK1 activity: ↑ activaty of the GP130/STAT3 signaling | [48] | |
TMPO-AS1 and miR-143-3p | 16HBE, H1299, A549, 95D, and H125 | ∆ TMPO-AS1: ↓ cell viability, ↑ apoptosis TMPO-AS1 regulated CDK1 via targeting miR-143-3p | [49] | |
miR-181a | 16HBE,, H1299, and A549 | ↑↑ miR-181a: ↓ proliferation, colony formation, and invasion | [50] | |
miR-143 and miR-506 | HFL-1, A549, H358, H69-AR, H358, H1975, and Calu-3 | ↑↑ miR-143 and miR-506: ↓ cell growth via targeting CDK1 and CDK4 | [51] | |
miR-143 and miR-506 | A549, HUVECs | ↑↑ miR-143 and miR-506: ↓ angiogenesis, and ↑ cell cycle arrest via targeting CDK1, 4/6 genes, respectively | [52] | |
Melanoma | Sox2 | 1205Lu, WM239A, A375, and HCT116 | CDK1 was found to be a new regulator of Sox2, so had tumor-initiating capacity in melanoma | [53] |
CHPF | A375 | CHPF was found to play its oncogenic role by regulating of CDK1 in malignant melanoma | [54] | |
Myeloid leukemia | EZH2 and DNMT3A | NIH3T3, 293T, and OCI-AML3 | ↑↑ DNMT3A mutation-induced CDK1: ↑ proliferation and ↓ apoptosis via modulating the interaction between EZH2 and DNMT3A | [55] |
Nasopharyngeal carcinoma | cyclin B1 | 5-8F and 6-10B NPC | Proteasome inhibitors were found to participate in the accretion of CDK1/cyclin B1, so decreased paclitaxel-induced cell death | [56] |
CDC25C/CDK1/Cyclin B1 pathway | CNE1 and CNE2 | appropriate dose of tetrandrine and irradiation treatment: ↓ phosphorylation of CDK1 and CDC25C and ↑ expression of cyclin B1, ↑ cell cycle arrest | [57] | |
miR-195-3p | 5–8 F, 6–10B, CNE1, CNE2, C666-1, and NP69 | ↑↑ miR-195-3p: ↑ radiosensitivity via targeting CDK1 | [58] | |
Ovarian cancer | UBE2C | KOV3, A2780, SKOV3/DDP, and A2780/ DDP | ∆ UBE2C: ↓ proliferation, cisplatin resistance, and ↑ apoptosis via downregulating CDK1 | [59] |
Chk1-CDC25C and P53-P21WAF1 signaling pathway | SK-OV-3 and OVCAR-3 | ∆ CDK1: ↓ proliferation, ↑ cell cycle arrest, and cell apoptosis | [60] | |
TONSL-AS1 and miR-490-3p | OVCAR3 OEC cell line | ↑↑ TONSL-AS1: ↑ proliferation via targeting miR-490-3p and regulating CDK1 | [61] | |
DLEU1/miR-490-3p/CDK1 axis | OVCAR3 and A2780 | ↑↑ DLEU1: ↑ proliferation, migration, and invasion, and ↓ apoptosis DLEU1 was found to sponge miR-490-3p, so regulate CDK1 | [62] | |
Pancreatic cancer | KRas | MiaPaCa2, Panc1, L3.6pl, A549, A427, H460, Calu6, SW620, DLD1, HCT8 | AT7519, (a CDK1, 2, 7, and 9 inhibitor) induces apoptosis CDK hyperactivation was linked with mt KRas dependency | [63] |
miR-143 and miR-506 | Panc-1 and MIA-PaCa-2 | ↑↑ miR-143 and miR-506: ↓ cell growth via targeting CDK1 and CDK4 | [51] | |
Pancreatic ductal adenocarcinoma | _ | PATU-T, Hs766T, and HPAF-II | Oxadiazole-based topsentin derivative (compound 6b): ↓ CDK1 expression, and ↑ apoptosis | [64] |
_ | different cell lines | Inaciclib was found to be an immune checkpoint inhibitor ∆ CDK1/2/5: ↓ UN-dependent STAT1 expression and activation, ↑ caspase-dependent apoptosis and histone-dependent ICD | [65] | |
Prostate cancer | TPX2, ERK/GSK3β/SNAIL signaling pathway | BPH-1, LNCaP, C4-2, PC-3, 22RV1 | ∆ TPX2: ↓ cell activity and migration, EMT process, ↓ expression of CDK1, ↓ the phosphorylation of ERK/GSK3β/SNAIL | [66] |
ABCC5 | C4-2, VCaP, ENZ-R, C4-2 and 22Rv1 | ↑↑ ABCC5: ↑ progression of cancer and resistance to Enzalutamide via the CDK1-mediated phosphorylation of AR ABCC5 was found to inhibit ubiquitination of CDK1 via binding to CDK1 ∆ CDK1: ↑ sensitivity to enzalutamide | [67] |